New hope for advanced liver cancer: drug duo tested in phase 2 trial

NCT ID NCT05257590

Recruiting now Disease control Sponsor: TaiRx, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hepatocellular carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER HEPATOCELLULAR CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Kaohsiung Chang Gung Memorial Hospital
RECRUITING

Kaohsiung City, Taiwan

Contact
Keelung Chang Gung Memorial Hospital
RECRUITING

Keelung, Taiwan

Contact
National Cheng Kung University Hospital
RECRUITING

Tainan, Taiwan

Contact
National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan

Contact
Taipei Veterans General Hospital
RECRUITING

Taipei, 112, Taiwan

Contact